Plain-English translation of NCT06355037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and , when combined with chemotherapy, can help your cancer respond better to treatment. Some breast cancers stop responding to chemotherapy over time—a problem called drug resistance. This study explores whether these two medications, given together with your regular chemotherapy, might reverse that resistance and make the chemotherapy work more effectively against your cancer.
When triple-negative breast cancer comes back or keeps growing despite chemotherapy, doctors have limited options. Early laboratory studies suggest this medication combination might help restore chemotherapy's effectiveness by targeting cells that contribute to drug resistance, but this needs to be tested in real patients.
You would receive the two study medications ( and ) by mouth alongside your regular chemotherapy treatment. The study is small—enrolling only about 10 patients—and researchers will carefully monitor your health with blood tests and imaging scans to see how well the combination works and to watch for any side effects. Your doctor will track how your cancer responds and how you tolerate the treatment over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~10 participants
Started
May 2024
Primary completion
December 2024
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhimin Shao, MD, PhD
Fudan University